Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation

International Journal of Cardiology

Volumn 126, Issue 3, 2008, Pages 316-321

  Ohara, Kazumasa ^a   Inoue, Hiroshi ^a   Nozawa, Takashi ^a   Hirai, Tadakazu ^a   Iwasa, Atsushi ^b   Okumura, Ken ^b   Lee, Jong Dae ^c   Shimizu, Akihiko ^d   Hayano, Motonobu ^e   Yano, Katsusuke ^e  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

^d YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NAGASAKI UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Embolic risk; Hemostatic markers; Warfarin

Indexed keywords

BETA THROMBOGLOBULIN; D DIMER; PROTHROMBIN; THROMBOCYTE FACTOR 4; WARFARIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

AGE DISTRIBUTION; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BETA-THROMBOGLOBULIN; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLATELET FACTOR 4; PROBABILITY; PROTHROMBIN; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STROKE; SURVIVAL ANALYSIS; THROMBOEMBOLISM; WARFARIN;

EID: 43249091408     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.06.020     Document Type: Article

References (32)

1. Hart R.G., Benavente O., McBride R., and Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131 (1999) 492-501
2. Gustafsson C., Blomback M., Britton M., Hamsten A., and Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 21 (1990) 47-51
3. Kumagai K., Fukunami M., Ohmori M., Kitabatake A., Kamada T., and Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 16 (1990) 377-380
4. Lip G.Y., Lowe G.D., Rumley A., and Dunn F.G. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J 131 (1996) 724-730
5. Sohara H., Amitani S., Kurose M., and Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 29 (1997) 106-112
6. Kamath S., Blann A.D., Chin B.S., and Lip G.Y. Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation. Heart 89 (2003) 1093-1095
7. BAATAF Investigators. Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. Stroke 24 (1993) 1360-1365
8. Feinberg W.M., Pearce L.A., Hart R.G., et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 30 (1999) 2547-2553
9. Li-Saw-Hee F.L., Blann A.D., and Lip G.Y. Effect of degree of blood pressure on the hypercoagulable state in chronic atrial fibrillation. Am J Cardiol 86 (2000) 795-797
10. Feng D., D'Agostino R.B., Silbershatz H., et al. Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am J Cardiol 87 (2001) 168-171
11. Conway D.S., Pearce L.A., Chin B.S., Hart R.G., and Lip G.Y. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 106 (2002) 1962-1967
12. Inoue H., Nozawa T., Okumura K., Lee J.D., Shimizu A., and Yano K. Prothrombotic activity is increased in patients with nonvalvular atrial fibrillation and risk factors for embolism. Chest 126 (2004) 687-692
13. Nozawa T., Inoue H., Hirai T., et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 109 (2006) 59-65
14. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., and Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001) 2864-2870
15. Inoue H., Nozawa T., Hirai T., et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 70 (2006) 651-656
16. Lip G.Y., Lowe G.D., Rumley A., and Dunn F.G. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 73 (1995) 527-533
17. Lip G.Y., Lip P.L., Zarifis J., et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 94 (1996) 425-431
18. Li-Saw-Hee F.L., Blann A.D., and Lip G.Y. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 31 (2000) 828-833
19. Kamath S., Blann A.D., Chin B.S., and Lip G.Y. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 40 (2002) 484-490
20. Nozawa T., Inoue H., Iwasa A., et al. Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation. Circ J 68 (2004) 29-34
21. Lip G.Y., and Li-Saw-Hee F.L. Does hypertension confer a hypercoagulable state?. J Hypertens 16 (1998) 913-916
22. Lip G.Y., Lowe G.D., Metcalfe M.J., Rumley A., and Dunn F.G. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 76 (1995) 453-458
23. Aso Y., Fujiwara Y., Tayama K., Takebayashi K., Inukai T., and Takemura Y. Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes. Clin Chim Acta 301 (2000) 135-145
24. Banga J.D. Coagulation and fibrinolysis in diabetes. Semin Vasc Med 2 (2002) 75-86
25. Koefoed B.G., Feddersen C., Gullov A.L., and Petersen P. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation. Thromb Haemost 77 (1997) 845-848
26. Yasaka M., Minematsu K., and Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 40 (2001) 1183-1188
27. Gage B.F., van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110 (2004) 2287-2292
28. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (2006) e257-e354
29. Singer D.E., Albers G.W., Dalen J.E., Go A.S., Halperin J.L., and Manning W.J. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 429S-456S
30. Lip G.Y., Lane D., Van Walraven C., and Hart R.G. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 37 (2006) 2294-2300
31. Yamaguchi T., and for Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. A multicenter, prospective, randomized trial. Stroke 31 (2000) 817-821
32. Jones M., McEwan P., Morgan C.L., Peters J.R., Goodfellow J., and Currie C.J. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 91 (2005) 472-477